5-((Trityloxy)methyl)pyrrolidin-2-one

• 分子结构分类: 有机化合物 - 苯类化合物 - 三苯基化合物
• 英文名称: 5-((Trityloxy)methyl)pyrrolidin-2-one
• 英文别名: 5-(trityloxymethyl)pyrrolidin-2-one
• 化学式: C₂₄H₂₃NO₂
• 分子量: 357.4
• InChiKey: FQSSRLVFPQIRJK-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.2
• 重原子数：
  27
• 可旋转键数：
  6
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.21
• 拓扑面积：
  38.3
• 氢给体数：
  1
• 氢受体数：
  2

文献信息

• Novel Compounds 002
  申请人：Beha Sara

  公开号：US20090062251A1

  公开（公告）日：2009-03-05

  Compounds of Formulae I, or pharmaceutically acceptable salts thereof: wherein R 1 , R 2 and Y are as defined in the specification as well as salts and pharmaceutical compositions including the compounds are prepared. They are useful in therapy, in particular in the management of pain.

  式I的化合物，或其药用可接受的盐： 其中R1、R2和Y如规范中定义的那样，以及包括这些化合物的盐和药物组合物已经准备好。它们在治疗中很有用，特别是在疼痛管理中。
• [EN] 1-(2-(ETHYLAMINO)PYRIMIDIN-4-YL)PYRROLIDIN-2-ONES AS INHIBITORS OF MUTANT IDH<br/>[FR] 1-(2-(ÉTHYLAMINO)PYRIMIDIN-4-YL)PYRROLIDIN-2-ONES EN TANT QU'INHIBITEURS DU MUTANT IDH
  申请人：NOVARTIS AG

  公开号：WO2014147586A1

  公开（公告）日：2014-09-25

  The invention is directed to a formula (I): (I) or a pharmaceutically acceptable salt thereof, wherein R1a–R1f, R2, R3 and R4 are described herein. The invention is also directed to compositions containing a compound of formula (I) and to the use of such compounds in the inhibition of mutant IDH proteins having a neomorphic activity. The invention is further directed to the use of a compound of formula (I) in the treatment of diseases or disorders associated with such mutant IDH proteins including, but not limited to, cell-proliferation disorders, such as cancer.

  该发明涉及一种化合物(I)的公式：(I)或其药学上可接受的盐，其中R1a-R1f，R2，R3和R4如本文所述。该发明还涉及含有化合物(I)的组合物，以及利用这些化合物抑制具有新型活性的突变IDH蛋白。该发明还涉及利用化合物(I)治疗与这些突变IDH蛋白相关的疾病或疾病，包括但不限于细胞增殖异常，如癌症。
• [EN] SELECTIVE ANDROGEN RECEPTOR MODULATORS<br/>[FR] MODULATEURS SÉLECTIFS DU RÉCEPTEUR DES ANDROGÈNES
  申请人：RADIUS HEALTH INC

  公开号：WO2012047617A1

  公开（公告）日：2012-04-12

  This invention provides compounds of formula I, pharmaceutical compositions comprising a compound of formula I and a pharmaceutically acceptable excipient, methods of modulating the androgen receptor, methods of treating diseases beneficially treated by an androgen receptor modulator (e.g., sarcopenia, prostate cancer, contraception, type 2 diabetes related disorders or diseases, anemia, depression, and renal disease) and processes for making compounds and intermediates useful in the preparation of same.

  该发明提供了公式I的化合物，包括公式I化合物和药学上可接受的赋形剂的药物组合物，调节雄激素受体的方法，治疗通过雄激素受体调节剂有益治疗的疾病的方法（例如，肌少症、前列腺癌、避孕、与2型糖尿病相关的疾病或疾病、贫血、抑郁症和肾脏疾病），以及制备用于制备相同物质的化合物和中间体的过程。
• [EN] JUN KINASE INHIBITORS<br/>[FR] INHIBITEURS DE KINASES JUN
  申请人：EISAI CO LTD

  公开号：WO2002081475A1

  公开（公告）日：2002-10-17

  The present invention provides novel compounds of formula (I) and their use in the inhibition of c-Jun N-terminal kinases. The present invention further provides the use of these compounds in medicine, in particular in the prevention and/or treatment of neurodegenerative disorders related to apoptosis and/or inflammation.

  本发明提供了式（I）的新化合物及其在抑制c-Jun N-末端激酶中的应用。本发明进一步提供了这些化合物在医学上的应用，特别是在预防和/或治疗与细胞凋亡和/或炎症有关的神经退行性疾病中的应用。
• Jun kinase inhibitors
  申请人：——

  公开号：US20040235864A1

  公开（公告）日：2004-11-25

  The present invention provides novel compounds of formula I 1 and their use in the inhibition of c-Jun N-terminal kinases. The present invention further provides the use of these compounds in medicine, in particular in the prevention and/or treatment of neurodegenerative disorders related to apoptosis and/or inflammation.

  本发明提供了I1式新化合物及其在抑制c-Jun N末端激酶中的应用。本发明还提供了这些化合物在医学上的应用，特别是在预防和/或治疗与细胞凋亡和/或炎症相关的神经退行性疾病方面的应用。